Rapt Therapeutics (United States)

Recent papers from Rapt Therapeutics (United States)

1. Selective γ8 transmembrane α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor regulatory protein negative allosteric modulators: Efficacy in preclinical antiseizure modelsEpilepsia · 2026
2. Exploratory definition of a clinically meaningful change in intracranial EEG features: Analysis of data from a long-term treatment study of the RNS® SystemEpilepsy & Behavior · 2026
3. Tahoe-100M: Mapping drug-induced molecular phenotypes at single-cell resolutionCell · 2026
4. Autism mutations rewire protein interaction networks to drive neurodevelopmental pathologyScience · 2026
5. ALG ‐020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug‐Induced Liver InjuryJournal of Viral Hepatitis · 2026
6. Oncogenic KRAS Rewires mRNA Stability and Translation through AGO2-Mediated Disruption of the miRNA pathwayCancer Research · 2026
7. Valbenazine Improves Quality of Life, Functionality, and Movement Severity in Patients With Tardive Dyskinesia: Findings From the KINECT-PRO™ StudyCNS Spectrums · 2026
8. Development and Characterization of a Long-Acting Allosteric Growth Hormone Receptor Antagonist for AcromegalyEndocrinology · 2026
9. Advancing Therapeutic Development in SCN2A and SCN8A -Related Disorders: A Multi-Stakeholder, Patient-Centric Roadmapping and Strategy WorkshopJournal of Clinical and Translational Science · 2026
10. ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial˜The œLancet. Gastroenterology & hepatology · 2026
11. Ozureprubart, a next-gen anti-IgE antibody, inhibits IgE binding to FcαRI, dissociates FcαRI-bound IgE, and reduces FcαRI expression on basophils 2258455The Journal of Immunology · 2026
12. Engagement With the Recovery Record App and Treatment Outcomes for Adolescents and Young Adults With Eating DisordersEuropean Eating Disorders Review · 2026
13. Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor ImmunityJournal of Medicinal Chemistry · 2026
14. The biological role of CCR4 and its ligands CCL17 and CCL22 in atopic dermatitis: therapeutic implications and future directionsExpert Opinion on Therapeutic Targets · 2026
15. Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialNature Medicine · 2026
16. Drug transporters in drug disposition – highlights from the year 2025Drug Metabolism Reviews · 2026
17. Neuron-specific WWOX gene therapy produces dose-dependent, durable rescue in a model of WWOX-related epileptic encephalopathyMolecular Therapy Advances · 2026
18. GPR35 modulates Na V 1.9 gating and sensory neuron excitabilityBritish Journal of Pharmacology · 2026
19. Phase 1 clinical trial investigating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AB821 in adult patients with locally advanced or metastatic melanoma and other solid tumor malignancies (NCT 07027488).Journal of Clinical Oncology · 2026
20. Phase 1A/B study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab, in patients with advanced solid tumor malignancies.Journal of Clinical Oncology · 2026